Relay Therapeutics Inc (RLAY)

$7.35 -0.28 (-3.67%)
Market Cap 1.40B
Revenue (ttm) 10.01M
Net Income (ttm) -337.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,373.73%
Debt to Equity Ratio 0.00
Volume 2,948,626
Avg Vol 2,191,876
Day's Range N/A - N/A
Shares Out 173.32M
Stochastic %K 3%
Beta 1.55
Analysts Strong Sell
Price Target $14.60

Company Profile

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGa...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 370 8837
Address:
399 Binney Street, 2nd Floor, Cambridge, United States
BillionerOfKing
BillionerOfKing Jan. 16 at 3:44 AM
$RLAY Current Stock Price: $7.62 Contracts to trade: $10 RLAY Jan 16 2026 Call Entry: $0.23 Exit: $0.43 ROI: 90% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 13 at 4:07 PM
$RLAY Dead $$
0 · Reply
UgoGreg
UgoGreg Jan. 10 at 3:38 PM
$RLAY https://youtu.be/ygBN8MilTyc
0 · Reply
Personalizit1
Personalizit1 Jan. 8 at 2:23 AM
$RLAY looks like 8ish is support
1 · Reply
BigDaddyCapital
BigDaddyCapital Jan. 7 at 7:08 PM
$RLAY this shit was up to $8.60 then ends up red on XBI nearly 2% day… yikes
1 · Reply
DARKP00L
DARKP00L Jan. 6 at 6:48 PM
$RLAY this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
garygb
garygb Jan. 5 at 6:40 PM
$RLAY Room to run
0 · Reply
BigDaddyCapital
BigDaddyCapital Jan. 2 at 6:11 PM
$RLAY incredibly bearish flow but no volume
0 · Reply
AlveoliAlpha
AlveoliAlpha Dec. 27 at 5:15 AM
$RLAY Sentiment increasingly tracks operational truth rather than guidance tone. Forecast reliability has room to improve materially. Predictability would attract a deeper institutional audience. Sentiment should follow confirmed results rather than headlines.
0 · Reply
Philox
Philox Dec. 19 at 3:50 PM
$RLAY looks like it’s on an uptrend! There are some promising breast Cancer treatments in the pipeline. Thoughts on this company?
2 · Reply
Latest News on RLAY
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

Dec 12, 2025, 7:00 AM EST - 5 weeks ago

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 3:23 AM EST - 7 weeks ago

Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

Nov 6, 2025, 4:05 PM EST - 2 months ago

Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

Nov 3, 2025, 4:05 PM EST - 2 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

Oct 30, 2025, 4:05 PM EDT - 2 months ago

Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

Relay Therapeutics Is A Buy For Its Superb Safety Data

Oct 24, 2025, 1:21 PM EDT - 3 months ago

Relay Therapeutics Is A Buy For Its Superb Safety Data

Relay Therapeutics, Inc. (RLAY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 2:33 PM EDT - 4 months ago

Relay Therapeutics, Inc. (RLAY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

Aug 28, 2025, 4:05 PM EDT - 5 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Relay Therapeutics: What's Next For H2 2025?

Aug 2, 2025, 8:03 AM EDT - 5 months ago

Relay Therapeutics: What's Next For H2 2025?

Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

Jul 31, 2025, 4:05 PM EDT - 6 months ago

Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

Jun 11, 2025, 4:05 PM EDT - 7 months ago

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

Jun 2, 2025, 7:00 AM EDT - 8 months ago

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 29, 2025, 4:05 PM EDT - 8 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

May 8, 2025, 4:05 PM EDT - 9 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

May 5, 2025, 4:05 PM EDT - 9 months ago

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

Apr 28, 2025, 4:05 PM EDT - 9 months ago

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

Relay Therapeutics: Trying To Find That Right Price

Apr 12, 2025, 9:28 AM EDT - 9 months ago

Relay Therapeutics: Trying To Find That Right Price

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Feb 26, 2025, 4:05 PM EST - 11 months ago

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

Feb 19, 2025, 4:05 PM EST - 11 months ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

Relay Therapeutics: A Precision Oncology Play Worth The Risk

Feb 14, 2025, 2:17 AM EST - 1 year ago

Relay Therapeutics: A Precision Oncology Play Worth The Risk

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:05 PM EST - 1 year ago

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Dec 11, 2024, 6:00 AM EST - 1 year ago

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Dec 9, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Dec 3, 2024, 8:01 AM EST - 1 year ago

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Dec 3, 2024, 8:00 AM EST - 1 year ago

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nov 6, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion

Sep 16, 2024, 4:57 PM EDT - 1 year ago

Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11, 2024, 8:15 AM EDT - 1 year ago

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Sep 11, 2024, 8:06 AM EDT - 1 year ago

GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

GME WOOF

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Sep 10, 2024, 8:21 PM EDT - 1 year ago

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market

Sep 10, 2024, 2:50 PM EDT - 1 year ago

Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market

This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Sep 10, 2024, 10:03 AM EDT - 1 year ago

This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

JCI DK EQR ORCL

Relay Therapeutics Announces Proposed Public Offering of Common Stock

Sep 9, 2024, 4:34 PM EDT - 1 year ago

Relay Therapeutics Announces Proposed Public Offering of Common Stock

Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher

Sep 9, 2024, 2:16 PM EDT - 1 year ago

Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients

Sep 9, 2024, 11:30 AM EDT - 1 year ago

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients

Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study

Sep 9, 2024, 7:04 AM EDT - 1 year ago

Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

Sep 9, 2024, 6:55 AM EDT - 1 year ago

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

Sep 6, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608

Jun 5, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608

Relay Therapeutics to Participate in Upcoming Investor Conferences

May 21, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics to Participate in Upcoming Investor Conferences

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

May 13, 2024, 8:30 AM EDT - 1 year ago

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

May 2, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

Feb 26, 2024, 4:05 PM EST - 2 years ago

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Feb 22, 2024, 4:05 PM EST - 2 years ago

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

Feb 15, 2024, 4:05 PM EST - 2 years ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

BillionerOfKing
BillionerOfKing Jan. 16 at 3:44 AM
$RLAY Current Stock Price: $7.62 Contracts to trade: $10 RLAY Jan 16 2026 Call Entry: $0.23 Exit: $0.43 ROI: 90% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 13 at 4:07 PM
$RLAY Dead $$
0 · Reply
UgoGreg
UgoGreg Jan. 10 at 3:38 PM
$RLAY https://youtu.be/ygBN8MilTyc
0 · Reply
Personalizit1
Personalizit1 Jan. 8 at 2:23 AM
$RLAY looks like 8ish is support
1 · Reply
BigDaddyCapital
BigDaddyCapital Jan. 7 at 7:08 PM
$RLAY this shit was up to $8.60 then ends up red on XBI nearly 2% day… yikes
1 · Reply
DARKP00L
DARKP00L Jan. 6 at 6:48 PM
$RLAY this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
garygb
garygb Jan. 5 at 6:40 PM
$RLAY Room to run
0 · Reply
BigDaddyCapital
BigDaddyCapital Jan. 2 at 6:11 PM
$RLAY incredibly bearish flow but no volume
0 · Reply
AlveoliAlpha
AlveoliAlpha Dec. 27 at 5:15 AM
$RLAY Sentiment increasingly tracks operational truth rather than guidance tone. Forecast reliability has room to improve materially. Predictability would attract a deeper institutional audience. Sentiment should follow confirmed results rather than headlines.
0 · Reply
Philox
Philox Dec. 19 at 3:50 PM
$RLAY looks like it’s on an uptrend! There are some promising breast Cancer treatments in the pipeline. Thoughts on this company?
2 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Dec. 15 at 5:41 PM
$RLAY Boom. The safety data is the catalyst. Short interest better cover. This is now a prime M&A target for $PFE or $NVS. 10+ months PFS + clean safety = $$$ in oncology. Buying the dip.
1 · Reply
DARKP00L
DARKP00L Dec. 12 at 4:32 PM
$RLAY 11:31 on Dec. 12 2025 Wells Fargo Upgrades Relay Therapeutics to Overweight, Raises Price Target to $13 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 4:32 PM
Wells Fargo updates rating for Relay Therapeutics ( $RLAY ) to Overweight, target set at 6 → 13.
0 · Reply
Chunty67
Chunty67 Dec. 12 at 2:40 PM
$RLAY last long
0 · Reply
GSP
GSP Dec. 12 at 2:14 PM
My finalized gapper list for Friday (part 2): $TLRY $YCBD $PL $RLAY .
2 · Reply
notreload_ai
notreload_ai Dec. 12 at 1:52 PM
Wells Fargo upgrades $RLAY and $ZYME , raising price targets and highlighting potential 2026 growth from clinical data and cancer treatment opportunities. https://notreload.xyz/wells-fargo-upgrades-relay-therapeutics-and-zymeworks-stocks/
0 · Reply
xUltraCash
xUltraCash Dec. 12 at 1:44 PM
$RLAY rise……
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 12 at 1:09 PM
$RLAY (+6.5% pre) Relay Therapeutics (RLAY) Shares New Data from Zovegalisib Study https://ooc.bz/l/87317
0 · Reply
dixiebull
dixiebull Dec. 12 at 12:31 PM
$BEAT $KPLT $RLAY
0 · Reply
RonIsWrong
RonIsWrong Dec. 12 at 12:14 PM
$RLAY Relay Therapeutics Presents Subset Analysis Of Interim Phase 3 Data For Zovegalisib At SABCS 2025 Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongoing CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.(RLAY) , a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced a subset analysis of interim clinical data for zovegalisib (RLY-2608), the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα. These data are being presented today at the 2025 San Antonio Breast Cancer Symposium (SABCS).
0 · Reply
Megaduffman
Megaduffman Dec. 3 at 3:40 PM
$RLAY $CAPR
0 · Reply
RandomInvestor777
RandomInvestor777 Nov. 28 at 4:54 PM
$RLAY 2B buyout by JPM?
3 · Reply